Marinomed Biotech Announces Capital increase with subscription rights

Marinomed Biotech Announces Capital increase with subscription rights

EQS-Media / 19.03.2026 / 16:47 CET/CEST

Marinomed Biotech Announces Capital increase with subscription rights

• Corporate action to meet short-term capital requirements
• Corporate action supported by an institutional investor
• Public shareholders have the opportunity to participate in the capital
increase through subscription rights
• Preliminary figures for 2025

 

Korneuburg, Austria, March 19, 2026   Marinomed Biotech AG („Company“) has
decided, due to a short-term need for capital, to increase its share
capital by up to EUR 459,985 through the issuance of up to 459,985 new
shares (“New Shares”) and to carry out a capital increase. The goal of the
transaction is to generate gross proceeds of at least EUR 2 million for
the company.

The New Shares will be offered as part of a prospectus-exempt offering
pursuant to Article 1(4)(db) of Regulation (EU) 2017/1129 (“Prospectus
Regulation”), as amended, based on a document in accordance with Annex IX
of the Prospectus Regulation, which will be published prior to the
commencement of the public offering. The subscription offer is scheduled
to begin on March 26, 2026, and will have a statutory minimum duration of
two weeks. Any New Shares not subscribed for will be offered following the
subscription offer as part of a prospectus-exempt private placement (“rump
placement”) to eligible institutional investors and selected
non-institutional investors within the European Economic Area at the
subscription price. A binding commitment has already been received from an
institutional investor who, as of today, does not yet hold any shares in
the Company, to subscribe for and acquire New Shares in the aggregate
amount of EUR 1 million at the subscription price as part of the short
placement. In the past, due to the Company’s restructuring proceedings, it
was necessary and appropriate to exclude shareholders’ subscription rights
in connection with recent cash capital increases in order to ensure and
carry out a swift capital measure. As part of the current rights offering,
existing shareholders have the opportunity to participate in the capital
increase on a 4:1 basis (four existing shares entitle the holder to
subscribe for one new share) and to maintain their ownership stake in the
company’s share capital. The subscription price per new share has been set
at EUR 14.

Because the Company has not yet received sufficient payments from the
transfer of the Carragelose business to Unither Pharmaceuticals, the
Company has a short-term capital requirement to cover its anticipated
liquidity needs of approximately EUR 2 million until mid of the fiscal
year 2026. The net proceeds from the capital increase are therefore to be
used to fulfill the restructuring plan and close the financing gap.

“Marinomed’s business plan projects profits for 2026 and subsequent years,
which are expected to be generated through the successful marketing of our
flagship products, Budesolv and Tacrosolv. We expect to receive payments
in the range of several million euros from partnerships and the licensing
of our flagship products through deals currently in the pipeline. Because
there have been delays in the earn-out payments from the sale of the
Carragelose business, this capital measure will close this liquidity gap,
and shareholders have the opportunity to participate in the measure by
subscribing to new shares,” commented Andreas Grassauer, CEO of Marinomed.

Marinomed is also releasing preliminary and unaudited figures for the 2025
fiscal year today.

Preliminary Financial Figures for 2025

According to these figures, revenue rose to €7.7 million in 2025 (2024:
€4.7 million). This includes an advance payment of €5 million from the
sale of the Carragelose business. Other operating income of €19.5 million
includes a restructuring gain of €18.9 million as well as the Austrian
research grant. Preliminary personnel expenses amounted to €4.0 million in
2025, compared to €4.8 million in 2024. This reflects the initial
optimization measures implemented during the year. The Liquid assets
amounted to approximately €1 million as of December 31, 2025.

Profit and loss statement (in millions of euros)

  FY 2025 FY 2024
Revenue 7.7 4.7
Change in inventory 0 0
Other Operating Income 19.5 0.1
Cost of materials and other purchased services -1.4 -3.8
Personnel expenses -4.0 -4.8
Depreciation -0.3 -1.1
Other operating expenses -2.8 -2.8
Operating result 18.7 -7.6
Interest and similar expenses -0.5 -7.9
Result before taxes 18.1 -15.5
Income Tax -2.9 -0.1
Net income/loss 15.3 -15.4

 

Balance Sheet ASSETS (in millions of euros)

Assets FY 2025 FY 2024
Intangible Assets 0 0.1
Property, plant and equipment 4.5 4.8
Financial assets 0 0
Fixed assets 4.5 4.9
Supplies 0 0.5
Receivables and other assets 0.3 0.9
Cash on hand, bank balances 1.0 1.7
Current assets 1.3 3.2
Deferred revenue 0.1 0
Deferred tax assets 0.0 0.1
Total Assets 5.9 8.2

 

Balance Sheet LIABILITIES and EQUITY (in millions of euros)

Liabilities and Equity FY 2025 FY2024
Share capital 1,8 1.8
Capital reserves 43.4 42.3
Retained earnings 0.7 0.7
Net loss -55.7 -70.9
Equity -9.8 -26.2
Investment grants 0.2 0.2
Provisions 3.4 0.9
Bonds 3.0 0
Liabilities to banks 8.4 28.2
Advance payments received 0 0.5
Trade payables 0.2 1.7
Other Liabilities 0.6 2.8
Total Liabilities 12.1 33.2
Total Liabilities and Equity 5.9 8.2

Note: All figures for 2025 are preliminary and rounded. The results for
the full year 2025 will be published on April 22, 2026.

 

Note:
The Company will make use of the prospectus exemptions under Article
1(4)(db) and Article 1.5(ba) of Regulation (EU) 2017/1129 (“Prospectus
Regulation”), as amended, in connection with the offering of the New
Shares and the admission of the New Shares to trading on the Vienna Stock
Exchange. The document required for this purpose pursuant to Annex IX of
the Prospectus Regulation will be filed in electronic form with the
Financial Market Authority (FMA), as the competent authority of the home
Member State, prior to the commencement of the public offering and will be
made available to the public at the same time as it is filed with the FMA
on the website www.marinomed.com.

 

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: [1] https://www.marinomed.com.

 

For further inquiries contact:

Marinomed Biotech AG  
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [2]pr@marinomed.com
E-Mail: [3]ir@marinomed.com

 

Disclaimer

This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.

End of Media Release

══════════════════════════════════════════════════════════════════════════

Issuer: Marinomed Biotech AG
Key word(s): Finance

19.03.2026 CET/CEST This Press Release was distributed by [4]EQS Group

View original content: [5]EQS News

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
Market)
EQS News ID: 2294758

 
End of News EQS Media

2294758  19.03.2026 CET/CEST

https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2294758&application_name=news&site_id=apa_ots_austria~~

References

~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2294758&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=fe29d062b6d019bf9584ee2d546ccdb0&application_id=2294758&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender